Literature DB >> 22834733

The SOX family of genes in cancer development: biological relevance and opportunities for therapy.

Sandra D Castillo1, Montse Sanchez-Cespedes.   

Abstract

INTRODUCTION: It has been more that 20 years since the first SOX genes were discovered. Twenty SOX genes have now been identified in mammals and classified into groups with respect to protein identity. SOX family genes code for transcription factors that either activate or repress lineage-specific genes during embryonic development. Furthermore, SOX genes are altered in human genetic syndromes and malignancies, highlighting their involvement in development. AREAS COVERED: This paper reviews the role of SOX genes in embryonic development and human diseases, and describe their involvement in human cancers and possible use in cancer therapeutics. EXPERT OPINION: Since most SOX genes behave as oncogenes in many human cancers, their targeting has great therapeutic potential. However, novel specific therapies such as those recently developed against growth factor receptors based on monoclonal antibodies, small inhibitors and even small interfering RNA strategies are difficult to implement for transcriptional factors. Novel strategies are being developed to overcome some of these obstacles. Alternative approaches could indirectly tackle altered SOX genes by exploiting the related molecular networks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22834733     DOI: 10.1517/14728222.2012.709239

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  42 in total

1.  Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer.

Authors:  Apiwat Pugongchai; Andrey Bychkov; Pichet Sampatanukul
Journal:  Int J Exp Pathol       Date:  2018-01-08       Impact factor: 1.925

2.  dTcf/Pangolin suppresses growth and tumor formation in Drosophila.

Authors:  Shilin Song; Diana Andrejeva; Flávia C P Freitas; Stephen M Cohen; Héctor Herranz
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

3.  The regulation of SOX7 and its tumor suppressive role in breast cancer.

Authors:  Daniel B Stovall; Meimei Wan; Lance D Miller; Paul Cao; Dejan Maglic; Qiang Zhang; Martha R Stampfer; Wennuan Liu; Jianfeng Xu; Guangchao Sui
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

4.  SOX 1, contrary to SOX 2, suppresses proliferation, migration, and invasion in human laryngeal squamous cell carcinoma by inhibiting the Wnt/β-catenin pathway.

Authors:  Ning Yang; Yan Wang; Lian Hui; Xiaotian Li; Xuejun Jiang
Journal:  Tumour Biol       Date:  2015-06-04

5.  Does the Sex-Determining Region on the Y Chromosome (SRY) Correlate with Gender Disparity in Liver Disease?

Authors:  Xu-Feng Zhang; Yi Lv
Journal:  Dig Dis Sci       Date:  2015-02-10       Impact factor: 3.199

6.  miRNA-124 down-regulates SOX8 expression and suppresses cell proliferation in non-small cell lung cancer.

Authors:  Chao Xie; Yunwei Han; Yi Liu; Lei Han; Jie Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 7.  SOX7: from a developmental regulator to an emerging tumor suppressor.

Authors:  Daniel B Stovall; Paul Cao; Guangchao Sui
Journal:  Histol Histopathol       Date:  2013-11-29       Impact factor: 2.303

8.  SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma.

Authors:  Weijie Gu; Beihe Wang; Fangning Wan; Junlong Wu; Xiaolin Lu; Hongkai Wang; Yao Zhu; Hailiang Zhang; Guohai Shi; Bo Dai; Dingwei Ye
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

9.  UCHL3 promotes proliferation of colorectal cancer cells by regulating SOX12 via AKT/mTOR signaling pathway.

Authors:  Jiangning Li; Yang Zheng; Xiaofeng Li; Xue Dong; Weiyan Chen; Zhongying Guan; Chong Zhang
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 10.  Role of SOX family of transcription factors in central nervous system tumors.

Authors:  Arlet M Acanda de la Rocha; Nicolas Sampron; Marta M Alonso; Ander Matheu
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.